Importance of Altered Gene Expression of Metalloproteinases 2, 9, and 16 in Acute Myeloid Leukemia: Preliminary Study. (7th May 2021)

• Record Type: Journal Article
• Authors: Pietrzak, Jacek; Mirowski, Marek; Świechowski, Rafał; Wodziński, Damian; Wosiak, Agnieszka; Michalska, Katarzyna; Balcerczak, Ewa
• Other Names: Qian Liren Academic Editor.
• Is Part Of: Journal of oncology. Volume 2021(2021)
• Publication Date: 2021-05-07
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2021/6697975
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Acute myeloid leukemia is a group of hematological neoplasms characterized by a heterogeneous course and high mortality. The important factor in the neoplastic process is metalloproteinases, proteolytic enzymes capable of degrading various components of the extracellular matrix, which take an active part in modifying the functioning of the cell, including transformation to cancer cell. They interact with numerous signaling pathways responsible for the process of cell growth, proliferation, or apoptosis. In the present study, changes in the expression of MMP 2, MMP 9, and MMP 16 genes between patients with AML and people without cancer were examined. The impact of cytogenetic changes in neoplastic cells on the expression level of MMP 2, MMP 9, and MMP 16 was also assessed, as well as the impact of the altered expression on the effectiveness of the first cycle of remission-inducing therapy. To evaluate the expression of all studied genes MMP 2, MMP 9, and MMP 16, SYBR Green-based real-time PCR method was used; the reference gene was GAPDH . For two investigated genes MMP 2 and MMP 16, the lower expression level was observed in patients with AML when compared to healthy people. The MMP 9 gene expression level did not differ between patients with AML and healthy individuals which may indicate a different regulation of gene expression in acute myeloid leukemia. However, no correlation was observed between the genes' expression of all tested metalloproteinases and the result of cytoreductive treatment or the presence of cytogenetic changes. The obtained results show that the expression of MMP 2 and MMP 16 genes is reduced while the expression of MMP 9 is unchanged in patients with acute myeloid leukemia. This may indicate a different regulation of the expression of these genes, and possible disruptions in gene transcription or posttranscriptional mechanisms in the MMP 2 and MMP 16 genes, however, do not affect the level of MMP 9 expression. Obtained results in AML patients are in contrary to various types of solid tumors where increased expression is usually observed.